Physician profile
Peter Walsh
NPI 1255372736
$1,817.81
in general payments reported to CMS, 2019-2025
14 companies · $658 in 2025
The $658 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $234 · 2020: $19.39 · 2021: $86.18 · 2022: $160 · 2023: $323 · 2024: $338 · 2025: $658.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,318.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,318.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $370.90 | 2019-2025 | Stelara, Tremfya, Simponi Aria |
| Abbvie INC. | $344.46 | 2019-2025 | Skyrizi |
| Takeda Pharmaceuticals U.S.A., INC. | $289.56 | 2021-2025 | Entyvio, Eohilia, Gattex |
| Pfizer INC. | $164.97 | 2019-2025 | |
| Ardelyx, INC. | $153.44 | 2023-2025 | Ibsrela |
| Celgene Corporation | $120.77 | 2023-2024 | Zeposia |
| Intercept Pharmaceuticals, INC. | $86.78 | 2019-2023 | Ocaliva |
| Ipsen Biopharmaceuticals, INC | $66.47 | 2024-2025 | Iqirvo |
| Regeneron Healthcare Solutions, INC. | $64.23 | 2023-2025 | Dupixent |
| Aimmune Therapeutics, INC. | $57.27 | 2025 | Zenpep |
| Allergan, INC. | $49.39 | 2019-2020 | |
| Genzyme Corporation | $18.28 | 2024 | |
| Janssen Pharmaceuticals, INC | $16.34 | 2019 | |
| Tersera Therapeutics LLC | $14.95 | 2025 | Xermelo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Walsh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.